化合物 SB225002|T1955

SB225002
182498-32-4

￥196 1mg 起订

￥437 5mg 起订

￥628 10mg 起订

上海更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 化合物 SB225002

英文名称：: SB225002

CAS号：: 182498-32-4

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 98.79%

产品类别：: 抑制剂

货号：: T1955

Product Introduction

Bioactivity

名称	SB225002
描述	SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
细胞实验	Three esophageal squamous cell carcinoma cell lines WHCO1, WHCO5, and WHCO6 originally established from surgical biopsies of primary esophageal squamous cell carcinomas are cultured in DMEM containing 10% FCS at 37°C in a humidified atmosphere of 5% CO2. MTT assays are carried out using the Cell Proliferation kit I. Briefly, 1.5 × 103 cells are plated in 96-well plates in a final volume of 180 μL DMEM per well. SB 225002 (antagonist of CXCR2, 400 nM) is added to cells and 0.001% DMSO (solvent) is added as a control. After the indicated incubation period, 18 μL of the MTT labeling reagent (final concentration 0.5 mg/mL) is added to each well and incubated for 4 hours in a humidified atmosphere. One hundred eighty microliters of the solubilization solution are added to each well and the plates were left overnight at 37°C. The spectrophotometric absorbance of samples is measured at 595 nm using a microtiter plate reader.(Only for Reference)
激酶实验	Radioligand Binding Experiments: Assays are performed in 96-well microtiter plates where the reaction mixture contains 1.0 μg/ml membrane protein in 20 mM Bis-Tris-propane, pH 8.0, with 1.2 mM MgSO4, 0.1 mM EDTA, 25 mM NaCl, and 0.03% CHAPS and SB 225002 (10 mM stock in Me2SO) added at the indicated concentrations, the final Me2SO concentration is <1% under standard binding conditions. Binding is initiated by addition of 0.25 nM 125I-IL-8 (2,200 Ci/mmol). After 1-h incubation at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethyleneimine, 0.5% BSA and washed three times with 25 mM NaCl, 10 mM Tris·HCl, 1 mM MgSO4, 0.5 mM EDTA, 0.03% CHAPS, pH 7.4. The filter is dried, sealed in a sample bag containing 10 ml of Wallac 205 Betaplate liquid scintillation fluid, and counted with a Wallac 1205 Betaplate liquid scintillation counter.
体外活性	SB225002表现出长效的镇痛效果,并减少小鼠模型中TNBS诱导的结肠炎.在兔子中,SB225002选择性阻断IL-8诱导的嗜中性粒细胞的边缘化.在小鼠肝内胆管细胞癌模型中,1 mg/kg i.p. SB225002抑制皮下移植肿瘤的生长.
体内活性	SB225002显示了作为微管抑制剂的抗肿瘤活性。SB225002大大降低了磷酸化ERK1/2的水平,并降低了WHCO1细胞的细胞增殖。SB225002在体外实验中,抑制GROα刺激的钙动员,并有效地抑制由IL-8和GROα诱导的人和兔嗜中性粒细胞趋化性。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 55 mg/mL (156.19 mM) Ethanol : 3 mg/mL (8.51 mM), Heating is recommended.
关键字	SB-225002 \| CXC chemokine receptors \| CXCR \| Inhibitor \| inhibit \| SB225002 \| SB 225002
相关产品	Nicotinamide N-oxide \| Plerixafor octahydrochloride \| Plerixafor \| rac-NBI-74330 \| LIT927 \| CXCR2-IN-1 \| SX-682 \| Artemotil \| Reparixin \| AZD8309 \| CXCL-CXCR1/2-IN-1 \| Delmetacin
相关库	抑制剂库 \| 肿瘤免疫治疗小分子化合物库 \| 经典已知活性库 \| 已知活性化合物库 \| 细胞因子抑制剂库 \| ReFRAME 相关化合物库 \| 高选择性抑制剂库 \| NO PAINS 化合物库 \| GPCR靶点分子库 \| 膜蛋白靶向化合物库

SB225002|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子